Restylane Eyelight 1x0.5ml
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
Restylane Eyelight is Galderma's NASHA® gel formulated specifically for infraorbital hollowing and the tear trough. It is presented in a 0.5 ml syringe — the rest of the range is 1 ml — and is implanted in the supraperiosteal plane. It is the brand's first product developed with NASHA technology for volume loss under the eye.
- Cross-linked HA 20 mg/ml
- Lidocaine 3 mg/ml (0.3 %)
- Technology NASHA®
- Contents 1 syringe × 0.5 ml
- Needle 29G ½"
Composition and technology
- Cross-linked hyaluronic acid: 20 mg/ml, obtained by bacterial fermentation (Streptococcus spp.), cross-linked with BDDE and suspended in phosphate buffer solution.
- Lidocaine hydrochloride: 3 mg/ml (0.3 %).
- NASHA® technology: firm, particulate gel with minimal cross-linking. In the infraorbital area the firmness of the NASHA gel and its low water uptake are the argument against softer, more hydrophilic gels, which in this region tend to cause persistent oedema.
- 0.5 ml presentation: matched to the volume actually applied in the area; it avoids the surplus of a 1 ml syringe.
Position within the range: NASHA and OBT
The entire Restylane range is built on two different gel technologies. Choosing between them is the first clinical decision of the treatment.
NASHA® (Non-Animal Stabilized Hyaluronic Acid): firm, particulate gels that retain the long hyaluronic acid chains with minimal cross-linking. High resistance and very low tolerance to deformation: projection, definition and structural support in areas that must hold their shape.
OBT™ (Optimal Balance Technology, called XpresHAn Technology™ in the US market): soft, flexible gels with a variable degree of cross-linking. Low to intermediate resistance and high tolerance to deformation: the gel follows the movement of the tissue, so it is intended for dynamic and expressive areas.
| NASHA — firmness and projection | G′ 416–799 Pa · deformability 7–19 % |
|---|---|
| Restylane / Classyc Lidocaine | HA 20 mg/ml · G′ 701 Pa · 7 % — wrinkles in the mid dermis, lips |
| Restylane Lyft Lidocaine | HA 20 mg/ml · G′ 799 Pa · 17 % — cheekbones, mid third of the face, dorsum of the hands |
| Restylane Eyelight | HA 20 mg/ml — infraorbital hollowing, supraperiosteal plane |
| Restylane Skinboosters Vital / Vital Light | HA 20 and 12 mg/ml — skin quality and hydration, without volumetric purpose |
| OBT / XpresHAn — flexibility and expression | G′ 70–271 Pa · deformability 761–1,442 % |
| Restylane Refyne | HA 20 mg/ml · G′ 70 Pa · 1,442 % — moderate wrinkles and folds |
| Restylane Kysse | HA 20 mg/ml · G′ 160 Pa · 908 % — lips, submucosal plane |
| Restylane Volyme | HA 20 mg/ml · G′ 171 Pa · 930 % — malar volume, supraperiosteal or subcutaneous |
| Restylane Defyne | HA 20 mg/ml · G′ 271 Pa · 761 % — severe wrinkles and folds |
The G′ (0.1 Hz) and deformability (xStrain) values come from peer-reviewed literature (J Drugs Dermatol 2024;23(12):1332–1338). Galderma does not publish official rheological values.
Indications and treatment areas
Correction of infraorbital hollowing (volume deficit under the eye) in adult patients.
- Tear trough
- Infraorbital region and lid-cheek junction
The periorbital area requires strict patient selection: herniated fat pads, marked eyelid laxity or chronic oedema are not indications for filler.
Technique and treatment protocol
- Injection plane: supraperiosteal. Superficial injection can produce visible nodules or bluish discoloration (Tyndall effect) — the most frequent technical error in this region.
- Needle: 29G ½" co-packed. Blunt cannulas of 25 or 27G and 1½" were also used in the clinical studies.
- Volume: up to 1 ml per side and session. If more volume is required, schedule a touch-up session rather than increasing the dose.
- Technique: small supraperiosteal deposits, with minimal injection pressure and slow withdrawal.
- Prior aspiration in accordance with standard clinical protocol; the periorbital region concentrates the risk of serious vascular complications.
- Documented duration: 87.4 % responders at month 3 and 63.5 % at month 12, defined as an improvement of at least 1 point on the GIHS scale.
Technical data
| Manufacturer | Q-Med AB (Galderma) — Uppsala, Sweden |
|---|---|
| Active substance | Cross-linked hyaluronic acid 20 mg/ml, non-animal origin |
| Anaesthetic | Lidocaine hydrochloride 3 mg/ml (0.3 %) |
| Cross-linker | BDDE |
| Technology | NASHA® |
| Vehicle | Phosphate buffer solution |
| Presentation | 1 pre-filled syringe of 0.5 ml |
| Needle | 29G ½" (alternative used in the study: 25–27G 1½" cannula) |
| Application plane | Supraperiosteal |
| Maximum volume | 1 ml per side and session |
| Classification | CE-marked medical device (MDR 2017/745) |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: up to 25 °C. Protect from freezing and from sunlight.
- Do not use after the expiry date shown on the pack.
- Single-use product. Do not reuse or re-sterilise.
- The pack contains: 1 pre-filled syringe of 0.5 ml, sterile 29G ½" needle, instructions for use and traceability labels for the patient record.
Contraindications and warnings
Contraindications (Galderma instructions for use): known hypersensitivity to streptococcal proteins or to any component of the product; history of severe allergies or of an anaphylactic reaction; hypersensitivity to lidocaine or to amide-type local anaesthetics; porphyria; active skin inflammation or infection in the area to be treated.
Precautions and individual assessment: coagulation disorders or anticoagulant or antiplatelet therapy (increased risk of haematoma and bleeding at the puncture site); history of hypertrophic or keloid scarring; autoimmune disease; presence of permanent implants in the area.
Warnings: do not inject intravascularly or intramuscularly. Intravascular injection can cause embolisation, vascular occlusion, ischaemia, skin necrosis, visual disturbance, blindness or stroke. Aspiration before injecting and low, constant injection pressure are recommended. Do not mix the gel with other products.
Always consult the instructions for use included in the pack before application.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the manufacturer's official documentation (Restylane® Eyelight™ with lidocaine instructions for use, Q-Med AB / Galderma). This data sheet does not replace the instructions for use accompanying the product.